Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

54  +0.16 (+0.3%)

After market: 54 0 (0%)

Fundamental Rating

8

We assign a fundamental rating of 8 out of 10 to HALO. HALO was compared to 555 industry peers in the Biotechnology industry. HALO gets an excellent profitability rating and is at the same time showing great financial health properties. HALO is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HALO could be worth investigating further for value and growth and quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year HALO was profitable.
HALO had a positive operating cash flow in the past year.
In the past 5 years HALO has always been profitable.
HALO had a positive operating cash flow in each of the past 5 years.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO's Return On Assets of 22.10% is amongst the best of the industry. HALO outperforms 98.02% of its industry peers.
The Return On Equity of HALO (100.64%) is better than 99.28% of its industry peers.
HALO's Return On Invested Capital of 23.44% is amongst the best of the industry. HALO outperforms 98.20% of its industry peers.
HALO had an Average Return On Invested Capital over the past 3 years of 17.81%. This is above the industry average of 14.78%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(23.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROIC 23.44%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

The Profit Margin of HALO (44.76%) is better than 98.74% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a better Operating Margin (55.10%) than 100.00% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
HALO has a better Gross Margin (83.45%) than 87.21% of its industry peers.
In the last couple of years the Gross Margin of HALO has grown nicely.
Industry RankSector Rank
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so HALO is creating value.
HALO has less shares outstanding than it did 1 year ago.
The number of shares outstanding for HALO has been reduced compared to 5 years ago.
HALO has a better debt/assets ratio than last year.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 4.63 indicates that HALO is not in any danger for bankruptcy at the moment.
HALO's Altman-Z score of 4.63 is fine compared to the rest of the industry. HALO outperforms 76.40% of its industry peers.
HALO has a debt to FCF ratio of 3.04. This is a good value and a sign of high solvency as HALO would need 3.04 years to pay back of all of its debts.
HALO has a better Debt to FCF ratio (3.04) than 93.87% of its industry peers.
HALO has a Debt/Equity ratio of 3.13. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 3.13, HALO is not doing good in the industry: 82.70% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Altman-Z 4.63
ROIC/WACC3.19
WACC7.35%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

HALO has a Current Ratio of 8.39. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HALO (8.39) is better than 71.53% of its industry peers.
HALO has a Quick Ratio of 7.30. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 7.30, HALO is in the better half of the industry, outperforming 67.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 7.3
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

HALO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.77%, which is quite impressive.
HALO shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 30.12% yearly.
The Revenue has grown by 25.66% in the past year. This is a very strong growth!
The Revenue has been growing by 38.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%

3.2 Future

HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.77% yearly.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.63% yearly.
EPS Next Y32.62%
EPS Next 2Y32.37%
EPS Next 3Y30.59%
EPS Next 5Y16.77%
Revenue Next Year24.83%
Revenue Next 2Y21.37%
Revenue Next 3Y18.79%
Revenue Next 5Y12.63%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

10

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 11.87, which indicates a very decent valuation of HALO.
96.40% of the companies in the same industry are more expensive than HALO, based on the Price/Earnings ratio.
HALO is valuated cheaply when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 7.29, the valuation of HALO can be described as very cheap.
97.84% of the companies in the same industry are more expensive than HALO, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 21.90. HALO is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.87
Fwd PE 7.29
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.94% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, HALO is valued cheaper than 95.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.42
EV/EBITDA 10.05
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
HALO has an outstanding profitability rating, which may justify a higher PE ratio.
HALO's earnings are expected to grow with 30.59% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.36
PEG (5Y)N/A
EPS Next 2Y32.37%
EPS Next 3Y30.59%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (7/3/2025, 7:33:12 PM)

After market: 54 0 (0%)

54

+0.16 (+0.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners101.72%
Inst Owner Change-0.67%
Ins Owners0.82%
Ins Owner Change0.99%
Market Cap6.65B
Analysts76
Price Target71.98 (33.3%)
Short Float %9.09%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.72%
Min EPS beat(2)6.64%
Max EPS beat(2)14.79%
EPS beat(4)4
Avg EPS beat(4)16.48%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)11.76%
EPS beat(12)10
Avg EPS beat(12)11.39%
EPS beat(16)13
Avg EPS beat(16)12.38%
Revenue beat(2)2
Avg Revenue beat(2)7.09%
Min Revenue beat(2)1.36%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.53%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)4.78%
Revenue beat(12)7
Avg Revenue beat(12)3.03%
Revenue beat(16)9
Avg Revenue beat(16)3.86%
PT rev (1m)1.44%
PT rev (3m)6.75%
EPS NQ rev (1m)4.24%
EPS NQ rev (3m)7.89%
EPS NY rev (1m)5.24%
EPS NY rev (3m)6.9%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.72%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.76%
Valuation
Industry RankSector Rank
PE 11.87
Fwd PE 7.29
P/S 6.14
P/FCF 13.42
P/OCF 13.21
P/B 13.8
P/tB N/A
EV/EBITDA 10.05
EPS(TTM)4.55
EY8.43%
EPS(NY)7.41
Fwd EY13.73%
FCF(TTM)4.02
FCFY7.45%
OCF(TTM)4.09
OCFY7.57%
SpS8.8
BVpS3.91
TBVpS-2.59
PEG (NY)0.36
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROCE 29.2%
ROIC 23.44%
ROICexc 36.94%
ROICexgc 96.44%
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
FCFM 45.72%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Debt/EBITDA 2.22
Cap/Depr 9.93%
Cap/Sales 0.75%
Interest Coverage 250
Cash Conversion 74.2%
Profit Quality 102.14%
Current Ratio 8.39
Quick Ratio 7.3
Altman-Z 4.63
F-Score9
WACC7.35%
ROIC/WACC3.19
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
EPS Next Y32.62%
EPS Next 2Y32.37%
EPS Next 3Y30.59%
EPS Next 5Y16.77%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%
Revenue Next Year24.83%
Revenue Next 2Y21.37%
Revenue Next 3Y18.79%
Revenue Next 5Y12.63%
EBIT growth 1Y56.46%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year50.06%
EBIT Next 3Y27.87%
EBIT Next 5Y15.57%
FCF growth 1Y88.07%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y80.4%
OCF growth 3Y16.96%
OCF growth 5YN/A